Key highlights
Life sciences landlords face high interest rates, vacant properties, and looming loan deadlines.
Only a quarter of new lab space in Greater Boston was pre-leased in the past year.
Softer demand and tighter biotech funding are pushing rents lower, even below $100 in Kendall Square.
Tenants are gaining leverage through concessions like turnkey builds, rent reimbursements, and free rent.
Strategic timing could unlock significant benefits for companies planning relocations.
Read More
Featuring David Thomann, Cushman & Wakefield
David Thomann, a leading voice in life sciences real estate at Cushman & Wakefield, offers a clear-eyed view of the market's current turbulence and where opportunities lie for tenants.
The Pressure Builds on Landlords
After years of rapid expansion, the life sciences real estate market is undergoing a major shift. Developers and landlords, once buoyed by strong demand and favorable financing, are now confronting rising interest rates and vacant buildings. Many construction loans are coming due, forcing owners to prioritize tenant cash flow just to stabilize operations.
Tenants Tighten Their Belts
On the other side of the table, life sciences companies are grappling with a tighter funding environment. This has led to a noticeable increase in sublease space and softened demand. As a result, rental rates are declining. Kendall Square, a marquee life sciences hub, recently dipped below the symbolic $100 per square foot threshold for the first time in years.
Tension Becomes Tenant Leverage
This evolving tension between landlords and lenders is opening new doors for tenants. With the balance of power shifting, many companies are reconsidering their real estate strategies. Waiting to relocate could yield better outcomes as landlords become more willing to negotiate. Concessions like turnkey lab builds, generous rent reimbursements, and extended free rent periods are already emerging in the market.
Looking Ahead to 2026
As 2025 winds down and 2026 approaches, industry watchers anticipate even more dramatic shifts. Ownership changes, repricing of properties, and continued tenant-friendly deals are on the horizon. For life sciences companies, timing and strategy could be the key to unlocking significant value in a rapidly transforming market.
